<?xml version="1.0" encoding="UTF-8"?>
<p>Lessons from HIV should also be drawn to improve access to treatment, especially by using low-cost generic drugs and promoting subsidised treatment. While HBV treatment is currently relatively financially accessible, costing between €5.10 and €6.80 per month, we recommend free access for mono-HBV patients, as user fees reduce adherence and treatment effectiveness, something already demonstrated for HIV.
 <xref rid="R27" ref-type="bibr">27 28</xref> With respect to HCV treatment, the large decrease in prices obtained recently for DAA with the arrival of generic drugs has led to those treatments becoming very cost-effective in Cameroon.
 <xref rid="R29" ref-type="bibr">29</xref> However, at current prices (approximately €580–€600 for a 12-week sofosbuvir-based regimen),
 <xref rid="R30" ref-type="bibr">30</xref> they will remain inaccessible for the large majority of the population if they are not subsidised.
</p>
